NASDAQ:OTIC

Otonomy (OTIC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.0085
$0.0085
50-Day Range
$0.01
$0.12
52-Week Range
$0.01
$2.54
Volume
N/A
Average Volume
937,525 shs
Market Capitalization
$582,479.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OTIC stock logo

About Otonomy Stock (NASDAQ:OTIC)

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

OTIC Stock News Headlines

Otonomy, Inc.: Otonomy Provides Corporate Update
Just Released: Insider's Secret to Trading Options
This Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.
Otonomy Provides Corporate Update
5 Investors Betting Big on Otonomy (OTIC) Stock
Why Is Otonomy (OTIC) Stock Up 97% Today?
Just Released: Insider's Secret to Trading Options
This Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.
See More Headlines
Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Profitability

Net Income
$-51,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
67,780,000
Market Cap
$582,479.50
Optionable
Optionable
Beta
1.54
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Paul E. Cayer
    President, CFO, Secretary & Chief Business Officer
  • Anna Stepannenko
    Vice President -Technical operations
  • Fabrice Piu
    Vice President-Research & Preclinical Development
  • David Skarinsky
    Vice President-Clinical
  • Jeffery J. Anderson
    Vice President-Clinical Sciences

OTIC Stock Analysis - Frequently Asked Questions

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) issued its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). During the same quarter in the prior year, the firm earned ($0.22) EPS.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

This page (NASDAQ:OTIC) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners